Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,717,840
  • Shares Outstanding, K 1,306,270
  • Annual Sales, $ 26,107 M
  • Annual Income, $ 4,628 M
  • 36-Month Beta 1.22
  • Price/Sales 4.04
  • Price/Cash Flow 6.41
  • Price/Book 5.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.02 +6.14%
on 02/09/18
89.54 -9.88%
on 01/29/18
-0.26 (-0.32%)
since 01/23/18
3-Month
71.40 +13.01%
on 11/28/17
89.54 -9.88%
on 01/29/18
+7.87 (+10.81%)
since 11/22/17
52-Week
63.76 +26.55%
on 06/16/17
89.54 -9.88%
on 01/29/18
+11.32 (+16.32%)
since 02/23/17

Most Recent Stories

More News
Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL

Fish & Richardson won a motion for Judgment as a Matter of Law (JMOL) that reversed a $2.5 billion jury verdict against its client Gilead Sciences Inc. in federal court in Delaware. On February 16, 2018,...

GILD : 80.72 (+1.66%)
Gilead Sciences Announces Senior Management Change

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that James Meyers, Executive Vice President, Commercial Operations, will retire. Mr. Meyers joined Gilead in 1996 as a regional sales...

GILD : 80.72 (+1.66%)
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer

Kite, a Gilead Company (Nasdaq:GILD) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo's zinc finger nuclease...

SGMO : 24.85 (-2.17%)
GILD : 80.72 (+1.66%)
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

Kite, a Gilead Company (Nasdaq: GILD) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo's zinc finger nuclease (ZFN)...

SGMO : 24.85 (-2.17%)
GILD : 80.72 (+1.66%)
Wired News - Gilead Sciences Rejoices as Federal Judge Reverses Judgement in $2.54 Billion Patent Infringement Case with Merck

LONDON, UK / ACCESSWIRE / February 21, 2018 / Active-Investors.com has just released a free research report on Gilead Sciences, Inc. (NASDAQ: GILD) ("Gilead"). If you want access to this report all you...

MRK : 54.89 (+0.59%)
GILD : 80.72 (+1.66%)
Today's Research Reports on Trending Tickers: Gilead Sciences and Abbott Laboratories

NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped...

ABT : 59.53 (+0.92%)
GILD : 80.72 (+1.66%)
Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva

Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.

NVS : 85.28 (+0.09%)
EXEL : 29.35 (+0.86%)
GILD : 80.72 (+1.66%)
ICPT : 61.80 (+3.78%)
Intercept Starts OCA Trial for NASH Patients With Cirrhosis

Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.

NVS : 85.28 (+0.09%)
EXEL : 29.35 (+0.86%)
GILD : 80.72 (+1.66%)
ICPT : 61.80 (+3.78%)
Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Gilead Sciences

NEW YORK, NY / ACCESSWIRE / February 12, 2018 / U.S. markets managed to finish in the green on Friday, despite concerns of rising interest rates and inflationary pressure. The Dow Jones Industrial Average...

GILD : 80.72 (+1.66%)
REGN : 322.70 (+2.18%)
3 ETFs to Watch on Biotech Earnings

Major Biotech companies report mixed Q4 results.

IBB : 110.37 (+1.80%)
BBH : 123.90 (+2.09%)
BIB : 58.92 (+3.17%)
GILD : 80.72 (+1.66%)
AMGN : 186.07 (+1.98%)
ALXN : 118.33 (+3.26%)
BIIB : 290.41 (+1.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 81.85
1st Resistance Point 80.63
Last Price 80.72
1st Support Level 78.68
2nd Support Level 77.95

See More

52-Week High 89.54
Last Price 80.72
Fibonacci 61.8% 79.69
Fibonacci 50% 76.65
Fibonacci 38.2% 73.61
52-Week Low 63.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.